Comparative Pharmacology
Head-to-head clinical analysis: MYCIFRADIN versus XERAVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCIFRADIN versus XERAVA.
MYCIFRADIN vs XERAVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis by causing misreading of mRNA and incorporation of incorrect amino acids into the growing peptide chain.
Eravacycline is a tetracycline-class antibacterial that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A-site. It exhibits activity against a broad range of Gram-positive, Gram-negative, and anaerobic bacteria, including many tetracycline-resistant strains due to modifications circumventing common resistance mechanisms.
1-2 g orally every 6 hours for 7-14 days. Or 500 mg intramuscularly every 12 hours.
200 mg intravenously over 60 minutes every 12 hours
None Documented
None Documented
Terminal elimination half-life is 9–12 hours in patients with normal renal function; may extend to >20 hours in impaired renal function, necessitating dose adjustment.
Terminal elimination half-life is approximately 42 hours (range 30-60 hours) in healthy subjects; prolonged in elderly patients and those with severe hepatic impairment.
Primarily renal excretion of unchanged drug via glomerular filtration; >90% of absorbed dose excreted unchanged in urine within 24 hours. Minor biliary excretion (<1%) with fecal elimination accounting for <1%.
Fecal (approximately 80-90% as unchanged drug); renal (less than 1% as unchanged drug).
Category C
Category C
Antibiotic
Antibiotic